All In Biotech

Drug Trial Radar · NCT06641076

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 960 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

960

Planned (sponsor's estimate)

Start

Oct 15, 2024

Primary completion

May 28, 2026

Study completion Feb 4, 2027

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.

Conditions

  • Arthritis, Psoriatic

Interventions

  • SonelokimabDrug

    Randomized treatment, parallel-group

  • PlaceboDrug

    Randomized treatment, parallel-group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Time frame: Week 16

Locations

182 sites in 20 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Avondale, Arizona

  • Clinical Site

    Chandler, Arizona

  • Clinical Site

    Flagstaff, Arizona

  • Clinical Site

    Mesa, Arizona

  • Clinical Site

    Phoenix, Arizona

  • Clinical Site

    Scottsdale, Arizona

  • Clinical Site

    Tucson, Arizona

  • Clinical Site

    San Diego, California

  • Clinical Site

    Upland, California

  • Clinical Site

    Avon Park, Florida

  • Clinical Site

    Clearwater, Florida

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Springfield, Illinois

  • Clinical Site

    Lake Charles, Louisiana

  • Clinical Site

    Baltimore, Maryland

  • Clinical Site

    Grand Blanc, Michigan

  • Clinical Site

    Leland, North Carolina

  • Clinical Site

    Salisbury, North Carolina

  • Clinical Site

    Statesville, North Carolina

  • Clinical Site

    Middleburg Heights, Ohio

  • Clinical Site

    Portland, Oregon

  • Clinical Site

    Memphis, Tennessee

  • Clinical Site

    Allen, Texas

  • Clinical Site

    Colleyville, Texas

  • Clinical Site

    Lubbock, Texas

  • Clinical Site

    Plano, Texas

  • Clinical Site

    Beckley, West Virginia

  • Clinical Site

    Pleven, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Rousse, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Stara Zagora, Bulgaria

  • Clinical Site

    Calgary, Canada

  • Clinical Site

    Trois-Rivières, Canada

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.